MDS Proteomics Buys 2,000 cDNAs from Kazusa DNA Research Institute | GenomeWeb

NEW YORK, Feb. 5 - MDS Proteomics has acquired roughly 2,000 disease-related, full-length cDNA clones from Japan's Kazusa DNA Research Institute, MDS said on Tuesday.

The three-year deal "is a major step" to help MDS meet its goal of discovering 1,000 new drug targets in the next five years, according to Frank Gleeson, president and CEO of MDS Proteomics.

Financial terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.